Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 22 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

0%

0 of 21 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
18(81.8%)
Phase 3
2(9.1%)
N/A
1(4.5%)
Phase 2
1(4.5%)
22Total
Phase 1(18)
Phase 3(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT07307794Phase 1Recruiting

To Evaluate the Adhesion of TK-254RX on Healthy Participants

Role: collaborator

NCT06866613Phase 3Completed

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Role: collaborator

NCT06871046Phase 3Completed

Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

Role: collaborator

NCT06773767Phase 1Completed

Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.

Role: collaborator

NCT06870422Phase 1Completed

To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.

Role: collaborator

NCT06823284Phase 1Completed

To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

Role: collaborator

NCT06247410Phase 2Completed

Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease

Role: lead

NCT06042192Phase 1Completed

Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.

Role: collaborator

NCT05883124Phase 1Completed

Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

Role: lead

NCT05853341Phase 1Completed

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Role: collaborator

NCT04790136Phase 1Completed

Cannabidiol Bioavailability Trial With Oral Multiple Dose Administration

Role: lead

NCT04505787Phase 1Completed

S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet

Role: lead

NCT03343912Phase 1Completed

Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings

Role: collaborator

NCT03659435Phase 1Completed

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

Role: lead

NCT03573050Phase 1Completed

Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase

Role: lead

NCT03363997Phase 1Completed

Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days

Role: collaborator

NCT02911298Phase 1Completed

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

Role: collaborator

NCT03018015Phase 1Completed

Ibuprofen Bioavailability Trial With Oral Single Dose Administration.

Role: lead

NCT02980458Phase 1Completed

Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

Role: lead

NCT01333930Not ApplicableCompleted

Placebo Controlled Study for Characterisation of Immunological Effects and Safety of Active O2

Role: collaborator